Navigation Links
Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
Date:9/16/2011

irus (HSV), and JC virus (JCV), for which there are no FDA-approved treatments or where patients have failed available treatments. There is no evidence of otherwise unexplained nephrotoxicity or myelosuppression in these immunocompromised patients. These data support positive interim results seen in CMX001's ongoing Phase 2 placebo-controlled clinical trial evaluating the safety, tolerability and ability of CMX001 to prevent or control CMV infection in R+ hematopoietic cell transplant (HCT) recipients.  

About CMX001

CMX001 is an oral Lipid-Antiviral-Conjugate (LAC) that delivers high intracellular levels of the active antiviral agent cidofovir-diphosphate.  Its broad spectrum activity against double-stranded DNA (dsDNA) viruses without the myelotoxicity and nephrotoxicity of current agents has the potential to improve outcomes for immunosuppressed patients.  In development for the treatment or prevention of life-threatening dsDNA viral diseases, more than 600 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols.  More than 300 of these individuals have received CMX001 under Emergency Investigational New Drug Applications (EINDs) or as part of the CMX001-350 Open-Label Study to help treat life-threatening dsDNA viral diseases for which there were no other therapeutic options.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  The growing body of evidence of CMX001's antiviral activity against all five families of dsDNA viruses that cause disease in humans, including smallpox, has strengthened the compound's potential as a dual-use product prescribed as a traditional pharmaceutical and stockpiled as a biodefense countermeasure.  

Clinical studies of CMX001 include an ongoing Phase 2 study for the prevention cytomegalovirus (CMV) in adult hematopoietic cell transplant patients (CMX001-201); a Phase 2 s
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a workshop ... New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists will ... that hyperspectral imaging can bring to examination procedures. ... Director of Product Development at ChemImage, will host ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com announces that ... its catalogue: North America Aesthetic Lasers ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North ... to 2020 Summary GlobalData,s new report, ... Outlook to 2020", provides key market data on ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... tightening technologyOCEANSIDE, N.Y., May 18 Ellman International, ... Administration (FDA) has granted clearance to Pelleve(TM), a ... mild to moderate facial wrinkles and rhytids for ... on clinical data demonstrating that a single treatment ...
... 18 When treating the diabetes ... all" approach to testing is not enough to ... at the American Association of Clinical Endocrinologists (AACE) ... http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b ) "We need to ...
Cached Medicine Technology:Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles 2Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles 3Taking a Hard-Line Approach to Cardiovascular Risks in the Diabetes Patient 2
(Date:8/30/2014)... commonly used to treat gout, before and after ... complications from this type of surgery, but it ... according to a study published by JAMA ... to coincide with its presentation at the European ... cardiac surgery include postpericardiotomy syndrome (the occurrence of ...
(Date:8/30/2014)... Serving contented clients since inception, #1 web design ... is now offering discount for Labor Day on all ... putting forward the best of web development technology before ... of professionals and web developers and designers has expertise ... critical issues of web development and can develop websites ...
(Date:8/30/2014)... "I had a handicapped friend who could ... an inventor from Wetumpka, Ala. "In order to help her ... shore, I came up with a way for her to ... prototype for the patent-pending Deezers to allow crutches to be ... use crutches, walkers, or canes at the beach. The device ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has ... and sleep apnea (a medical problem where the airway ... their bed partners of the rest they need to ... population snores and 20 million people in the United ... have been diagnosed and treated; and of those treated, ...
(Date:8/30/2014)... 2014 The new review published by Daily ... by Karen Brimeyer, who wanted to make her guide accessible ... guide is now easy to find in the form of ... guide, the author of the new method shares all her ... Gossip writes in its review that the leaky gut syndrome ...
Breaking Medicine News(10 mins):Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2
... ... Chief Executive ... Barr Laboratories, Inc., -- In this newly created ... and development, regulatory affairs, operations, quality, and sales and ...
... DENVER, March 28 Long-chain (seafood) omega-3,polyunsaturated fatty ... heart,brain and eye health, according to recent research ... PUFA Newsletter electronic publications.,Groundbreaking studies also show that ... dry eye syndrome., The effect of fish ...
... delivery more likely if either parent was born that way, ... one or both parents were born bottom first or feet ... twice as likely to be born the same way, Norwegian ... about one in 20 is born bottom first. Breech deliveries ...
... people and their families living with ... all types of ... hit television series "Heroes" and father of an 11-year-old son with,epilepsy ... to plan community awareness activities that will empower other,people living with ...
... 27 SEIU Spokesperson,Andrew McDonald said:, ... UHW-W leaders should focus on,helping 70,000 ... year. UHW-W members,deserve better than to ... by a distracted,UHW-W leadership.", For ...
... On March 25, 2008, The Honorable Dan,A. Polster, ... Liability Multi-District Litigation in the Northern District,of Ohio, ... Steering,Committee. One of these lawyers is Peter Burg ... Polster, and is responsible for conducting,pre-trial proceedings on ...
Cached Medicine News:Health News:Barr Pharmaceuticals, Inc. Executive Bios 2Health News:Barr Pharmaceuticals, Inc. Executive Bios 3Health News:Barr Pharmaceuticals, Inc. Executive Bios 4Health News:Omega-3 Fatty Acids Protect the Spinal Cord, Heart, Brain and Eyes 2Health News:Breech Birth May Be Determined by Genes 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: